J. Michael Pearson - Valeant

Valeant CEO J. Michael Pearson

Nouveau riche, nouveau influential

Name: J. Michael Pearson
Title: CEO, Valeant Pharmaceuticals

Love him or hate him, Valeant ($VRX) chief executive J. Michael Pearson's M&A strategy has helped the Canada-based drugmaker achieve exponential growth--and others in the industry have taken note.

The deal-happy CEO first met with the company's board as a consultant back in 2007, ultimately telling directors that their "current strategy is not only not working, it doesn't have much of a chance to be successful," according to The Globe and Mail. From there, the company took up Pearson's strategy--and it hasn't looked back since.

Pearson's way of doing things involves zeroing in on high-growth areas--both geographic and therapeutic--and making deals, and lots of them. Dermatology ranks high among those areas Pearson has targeted, with Valeant picking up skincare companies like Medicis in 2012 and Obagi Medical in 2013.

Eye care is another high priority for Pearson, and Valeant has been as active as anyone in the specialty field. Since acquiring its eye-drug business in a 2010 buyout of Aton, Valeant has nabbed companies like Eyetech and, more recently, Bausch + Lomb, completing its largest deal ever at $8.7 billion.

Whether Pearson's got some admirers out there or he just knows how to pick his spots, both fields have seen a recent flurry of dealmaking. And some analysts suspect the CEO has inspired at least a couple of Valeant's peers, notably Endo ($ENDP), whose helmsman Rajiv De Silva served as president of Valeant before joining the company last year. "De Silva is very well-informed by Valeant's playbook," Piper Jaffray analyst David Amsellem told Bloomberg in November.

There's certainly reason for other companies to want in on a piece of the revenue Pearson's methods have generated. As large as Valeant's appetite for acquisitions has been, Pearson's sales goals have been even bigger, and the company has gone from $3.4 billion in 2012 sales to 2014 guidance of $8.2 billion to $8.6 billion.

So when will the deal craze end? If Pearson has his way, his company will join the ranks of the top 5 drug companies by market cap before 2016 closes out, he announced last month. By his calculations, that means Valeant--with a current market cap of about $38.4 billion--has just under three years to reach about $150 billion.

"Unless you aim high, you don't achieve high," Pearson said on a conference call in January. "How we get there, we can't say at this time." 

-- Carly Helfand (email | Twitter)

For more:
Move over, Big Pharma. Valeant's CEO plans to elbow his way in
Which are pharma's top 4 innovators? Hint: It's not the big guys
Valeant, Endo chalk up new deals with $220M-plus specialty buys
Deal-happy Valeant eyes more buyouts, 'merger of equals'

J. Michael Pearson - Valeant
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.